General Statement of Disclosure:

CONSULTING FEES/HONORARIA: Amarin(SIGNIFICANT), HLS Therapeutics(SIGNIFICANT), AstraZeneca Pharmaceuticals(SIGNIFICANT), DalCor Pharmaceuticals(SIGNIFICANT), Pharmascience(SIGNIFICANT) EQUITY INTERESTS/STOCK OPTIONS: DalCor Pharmaceuticals(SIGNIFICANT) RESEARCH/RESEARCH GRANTS: Amarin(SIGNIFICANT), Esperion(SIGNIFICANT), Astra-Zeneca(SIGNIFICANT), Ceapro(SIGNIFICANT), DalCor Pharmaceuticals(SIGNIFICANT), Ionis(SIGNIFICANT), Novartis Corporation(SIGNIFICANT), Pfizer(SIGNIFICANT), Merck & Co., Inc.(SIGNIFICANT)

View Full Disclosure